GlobalRx Inc.

GlobalRx Inc. is a US-based company specializing in the international procurement and distribution of FDA-approved medications and medical devices, serving healthcare providers, hospitals, and patients with unmet clinical needs. Founded in 1996 and headquartered in Hillsborough, US, GlobalRx Inc. operates in the pharmaceutical distribution sector, focusing on FDA-approved products.

There are no known pivots in its business strategy or structure, nor any references to subsidiaries or parent companies. GlobalRx specializes in the international procurement and distribution of FDA-approved medications and medical devices, catering to a diverse client base that includes healthcare providers, hospitals, specialty importers, and patients with unmet clinical needs. The company's core offerings encompass a wide range of pharmaceutical products, including generic and brand-name medications, specialty medications for complex conditions, orphan drugs for rare diseases, over-the-counter healthcare products, and veterinary pharmaceuticals. These products are distinguished by their compliance with regulatory standards and quality assurance protocols.

GlobalRx operates across multiple international markets, ensuring that their services address the specific needs of healthcare systems in regions such as North America, Europe, Asia, and the Middle East. Through a comprehensive distribution network, GlobalRx enhances access to vital medications and medical solutions for underserved populations and those affected by drug shortages. GlobalRx generates revenue primarily through direct transactions with healthcare providers and distributors, who purchase a variety of pharmaceutical products and services. The company's transaction structure is based on Business-to-Business (B2B) relationships, with a focus on bulk sales to hospitals and specialty importers.

Clients engage in agreements encompassing both one-time purchases and long-term supply contracts, ensuring a steady flow of essential medications. Notably, GlobalRx's offerings include flagship products such as FDA-approved generic medications and specialized therapeutics, which are crucial for treating various health conditions. Revenue is further bolstered through tailored logistics services, including temperature-controlled shipping and inventory management, that support clinical trial logistics and emergency response planning. This operational model positions GlobalRx as a key partner in the pharmaceutical supply chain, driving sustained growth within the healthcare sector.

In January 2026, AOI Capital invested in GlobalRx Inc. , with financial terms undisclosed. The company plans to expand its product offerings, particularly with new FDA-approved medications targeting complex health conditions. Additionally, GlobalRx aims to penetrate new geographic markets, specifically targeting regions in Asia and the Middle East by the end of 2026.

This expansion will be supported by the recent funding, which is expected to enhance their distribution capabilities and logistical infrastructure.